Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics Inc. (BIOR) is a clinical-stage biotechnology company pioneering smart pill-based drug delivery systems for targeted and systemic therapies. This page provides investors and stakeholders with timely updates on the company’s progress in redefining treatment for gastrointestinal diseases and chronic conditions.
Access the latest press releases, clinical trial milestones, and financial reports related to Biora’s innovative platforms—including the NaviCap™ targeted colon release system and BioJet™ needle-free delivery technology. Stay informed about regulatory developments, research collaborations, and strategic partnerships shaping the future of oral biotherapeutics.
This resource is designed for efficient tracking of BIOR’s advancements in drug-device combinations and precision medicine. Bookmark this page or check back regularly for verified updates directly from the company and trusted financial news sources.
Biora Therapeutics (Nasdaq: BIOR) has been granted an extension by Nasdaq to regain compliance with listing requirements. The company now has until November 7, 2024 to meet the $50 million market value of listed securities rule and $1 bid price requirements for continued listing on The Nasdaq Global Market. CEO Adi Mohanty expressed optimism about upcoming company catalysts that could drive significant shareholder value. Biora is focused on developing innovative NaviCap™ and BioJet™ therapeutics platforms, which are part of their efforts to reimagine therapeutic delivery.
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key details of Biora's involvement include:
- A company presentation on Wednesday, September 11, 2024, at 2:00 PM Eastern time
- One-on-one investor meetings
- A live webcast of the presentation available at a provided link
A replay of the presentation will be accessible on Biora's website after the conference concludes. This participation offers Biora an opportunity to showcase its innovations and engage with potential investors in the biotech sector.
Biora Therapeutics (Nasdaq: BIOR) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Successful completion of Phase 1 clinical trial for BT-600, demonstrating precise drug delivery to the colon with low systemic exposure.
2. Secured up to $16M funding from existing investors.
3. Active partnership discussions for BioJet™ platform with multiple large pharma companies.
4. Q2 2024 financial results: Operating expenses $16.1M, net income $6.5M, diluted net loss per share $0.04.
5. Anticipating Phase 1B clinical study initiation for BT-600 in ulcerative colitis patients by end of 2024.
6. Expecting to conclude at least one partnership agreement for BioJet platform in the near term.
Biora Therapeutics (Nasdaq: BIOR) has secured a $16 million multiple-draw facility from existing convertible notes holders. This funding is intended to serve as a bridge to anticipated pharmaceutical partnerships. The company's CFO, Eric d'Esparbes, expressed gratitude for the continued support of their noteholders, highlighting that this investment is expected to fund Biora through important milestones. The decision to provide additional funding was influenced by active interest from pharmaceutical collaborators in Biora's BioJet™ platform and recent promising clinical trial results from their NaviCap™ platform.
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced it will report its financial results for the second quarter of 2024, which ended on June 30. The company will also provide a corporate update during a webcast and conference call scheduled for Monday, August 12, 2024, after the financial markets close.
The conference call will take place at 4:30 PM Eastern time / 1:30 PM Pacific time. Interested parties can access the call using the following details:
- Domestic: 1-877-423-9813
- International: 1-201-689-8573
- Conference ID: 13747616
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.
Key details of Biora's participation include:
- Company presentation on Tuesday, August 13, 2024, at 2:30 PM Eastern time
- One-on-one investor meetings
- Live webcast available at https://wsw.com/webcast/canaccord98/bior/2458676
- Replay of the presentation will be accessible on Biora's website after the conference
This participation provides an opportunity for Biora to showcase its innovations in therapeutic delivery to potential investors and industry professionals.
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher tissue exposure and lower systemic concentrations compared to conventional oral administration.
Key findings include:
- Colon tissue drug levels above IC50 at 24 hours post-dosing
- Projected tissue levels above IC90 through at least 16 hours after 5 mg or 10 mg doses
- Pan-colonic delivery achieved with evidence of drug exposure in distal colon
- Lower systemic drug exposure, potentially reducing toxicity risks
- NaviCap devices were well-tolerated with no early release and >95% colon entry detection
These results support BT-600's potential to improve ulcerative colitis treatment efficacy and validate the NaviCap platform for targeted GI drug delivery.
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative colitis (UC) and the potential benefits of colonic drug delivery. The Phase 1 trial results indicate that BT-600, which uses the NaviCap device to deliver tofacitinib directly to the colon, effectively targets affected tissues in UC patients. The event will include a live Q&A session, and a replay will be available online.
Biora Therapeutics has announced positive results from its Phase 1 clinical trial for BT-600, a drug-device combination aimed at treating ulcerative colitis (UC). The NaviCap™ platform, which delivers tofacitinib directly to colonic tissue, met all trial objectives, demonstrating effective drug absorption in the colon, including the distal colon. This Phase 1 trial involved 48 healthy volunteers and showed that BT-600 was well tolerated. The results also indicated lower systemic drug exposure compared to conventional oral delivery methods. Following these successful outcomes, Biora plans to advance BT-600 into a Phase 1b clinical trial targeting UC patients. A virtual event featuring key opinion leaders will be held on July 17 to discuss these findings and future plans.
Biora Therapeutics (Nasdaq: BIOR) will present preclinical data on its BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit in Boston from June 18–20, 2024.
The presentation, titled 'Empowering Peptide Self-Administration with Needle-Free Smart Capsules,' will be delivered by Dr. Sharat Singh on June 19 from 2:15 to 2:45 PM Eastern time.
Additionally, Dr. Singh will join a panel discussion on peptide drug delivery innovations earlier the same day. Selections from the presentation will be available on Biora's website post-event.
